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Abstract
Introduction: Plasmacytoid dendritic cells (pDCs) constitutively express two members of the Toll-like receptor (TLR)
family, TLR-9 and TLR-7, through which they can be stimulated to produce high levels of interferon (IFN)-a, a key
mediator of the pathogenesis of systemic lupus erythematosus (SLE). Given the known efficacy of
hydroxychloroquine (HCQ) in the treatment of SLE, we examined its ability to inhibit such pDC function in vivo.
Methods: Peripheral blood mononuclear cells (PBMCs) from SLE subjects treated or not with HCQ and from
healthy controls were stimulated with the TLR-9 agonist, CpG oligodeoxynucleotides (CpG-A ODN)-2216, and the
TLR-7 agonist, imiquimod. The proportion of monocytes, B cells, myeloid dendritic cells, pDCs, and natural killer
(NK) cells producing IFN-a and tumor necrosis factor alpha (TNF-a) was then analyzed by multiparameter flow
cytometry.
Results: After TLR-9/7 stimulation in both SLE and healthy subjects, significant production of IFN-a and TNF-a was
only observed in pDCs. TLR-7 and TLR-9 induced IFN-a and TNF-a production by pDCs from subjects with SLE was
decreased relative to that found in controls (TLR-9/IFN-a, P < 0.0001; TLR-9/TNF-a P < 0.0001; TLR-7/TNF-a P =
0.01). TLR-9 and TLR-7 induced IFN-a and TNF-a production by pDCs was severely impaired in 36% (TLR-9) and
33% (TLR-7) of SLE subjects. In almost all cases, these subjects were being treated with HCQ (HCQ vs. no HCQ:
impaired TLR-9/IFN-a, P = 0.0003; impaired TLR-7/IFN-a, P = 0.07; impaired TLR-9/TNF-a, P < 0.009; impaired TLR-7/
TNF-a, P < 0.01).
Conclusions: Treatment with HCQ is associated with impaired ability of pDCs from subjects with SLE to produce
IFN-a and TNF-a upon stimulation with TLR-9 and TLR-7 agonists.
Introduction
A growing body of evidence indicates that type I interfer-
ons, such as interferon-a (IFN-a), play a pivotal role in
the etiology and pathogenesis of systemic lupus erythe-
matosus (SLE), and single-nucleotide polymorphisms in
several key molecules important for IFN-a production
and action are associated with SLE [1,2]. Moreover, some
of these type I IFN pathway polymorphisms have been
shown to impact IFN-a levels and responsiveness in SLE
patients in vivo [3].
Plasmacytoid dendritic cells (pDCs) have been shown to
be the major source of IFN-a production in the peripheral
blood [4] and within lymph nodes [5], and these cells pro-
duce IFN-a after stimulation across TLR-7 and/or TLR-9
[6-8]. pDCs have also been implicated as key mediators of
pathogenesis in SLE [9,10]. However, a number of studies
have shown that SLE patients have circulating pDCs that
are reduced in number and/or are dysfunctional [11-13].
Since different cell types are known to produce type I IFN
in small quantities after microbial challenge [4], these
observations raise the possibility that other circulating
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cells (for example, those involved in the innate immune
system, such as monocytes or myeloid dendritic cells, and/
or those expressing TLR-9 and/or TLR-7, such as B cells)
are the source of IFN-a production in SLE.
Antimalarial agents, such as quinine, have long been
used in the treatment of SLE, first (in 1894) in the con-
text of cutaneous lupus and then, as hydroxychloroquine
(HCQ), in the context of SLE [14-17]. In a randomized,
double-blind, placebo-controlled study, SLE patients
treated with HCQ had fewer disease flares and severe dis-
ease exacerbations compared to those receiving a placebo
[18]. Despite some uncertainty regarding the exact
mechanism(s) underlying their various effects, the princi-
pal mechanism of action of agents such as HCQ relates
to their ability to increase the intracytoplasmic pH and to
thereby prevent acidification and maturation of endo-
somes [19,20]. IFN-a in SLE patients can be produced by
pDCs in response to continuous stimulation by circulat-
ing immune complexes [9] that are internalized by CD32
(FcgRIIA), with subsequent detection of DNA and RNA
by endosomal TLR-9 and TLR-7 in pDCs [10,21]. HCQ
would predictably block TLR-9/7 stimulation [22,23] and
thus play a beneficial role in the treatment of SLE.
Importantly, HCQ has been shown to inhibit the produc-
tion of IFN-a in pDCs in vitro, either after induction by
DNA-containing immune complexes [10] or upon stimu-
lation with TLR-9 agonists [13]. It is not clear, however,
whether the same effect occurs in vivo, that is, in the set-
ting of SLE patients treated with HCQ.
In the current study, we have addressed the above
questions directly in a cohort of patients with SLE, trea-
ted or not with HCQ, to determine the predominant cir-
culating cell subpopulation capable of IFN-a production




SLE subjects were recruited from the University of Califor-
nia, San Francisco (UCSF) Lupus Genetics Project collec-
tion [1,24]. From this cohort, we recruited 39 individuals
of European ancestry who fulfilled at least four of the
American College of Rheumatology criteria for SLE [25].
Disease activity was assessed using the Systemic Lupus
Activity Questionnaire (SLAQ) [26]. Subjects with the fol-
lowing criteria were excluded: acute infection or vaccina-
tion within the prior eight weeks, ongoing treatment with
chemotherapy (including cyclophosphamide) or radiother-
apy, or active viral hepatitis. Ten healthy gender-matched
blood donors served as controls. The University of Califor-
nia, San Francisco Committee on Human Research
approved the study and all subjects provided written
informed consent.
Preparation of PBMCs
Blood samples obtained from SLE and healthy control
subjects were collected into ethylenediaminetetraacetic
acid (EDTA) and peripheral blood mononuclear cells
(PBMCs) were prepared using a ficoll hypaque gradient.
Cells were washed in phosphate buffered saline (PBS)
and suspended in RPMI 1640 medium supplemented
with penicillin, streptomycin, and L-glutamine.
TLR stimulation
PBMCs (106) from SLE and control subjects were cul-
tured with the TLR-7 agonist, imiquimod, (5 μg/ml;
InvivoGen, San Diego, CA, USA), the TLR-9 agonist,
CpG-A ODN 2216 (5 μM; InvivoGen), the TLR-4 ago-
nist, lipopolysaccharide (0.05 μg/ml; InvivoGen), and
media for five hours at 37°C in 5% CO2. Brefeldin A
(GolgiPlug, BD Pharmingen, San Diego, CA, USA) was
added during the final three hours of stimulation to
block cytokine secretion.
Flow cytometry
The panels of antibodies used for phenotypic and intra-
cellular cytokine detection are described in Additional
file 1, Table S1. Cytokine detection and phenotyping
were performed by sequential cell surface and intracellu-
lar staining, following the manufacturer’s instructions.
Potential Fc receptors were blocked by incubating
PBMCs with mouse serum prior to the addition of spe-
cific mouse anti-human antibodies. Fluorescence acti-
vated cell sorting (FACS) analysis was performed on a
four-laser BD LSR-II flow cytometer, and data were ana-
lyzed using FlowJo software v9-3 (Treestar, Ashland,
OR, USA) and transferred into analysis and graphic soft-
ware including Excel (Windows, Seattle, WA, USA) and/
or GraphPad Prism5 (La Jolla, CA, USA). All analyses
were carried out without knowledge of the subject’s
clinical status, including treatment. The strategy used to
gate the different subsets of PBMCs is shown in Addi-
tional file 1, Figure S1.
Statistical analyses
Exact nonparametric two-tailed tests were used. The
Kruskal-Wallis One-Way Analysis of Variance on Ranks
(ANOVA) or the Mann-Whitney tests were used to
compare continuous variables. The Dunn’s multiple
comparison test was used for statistical correction of
multiple comparisons. The Fisher’s exact test was used
to compare dichotomous variables. The Spearman rank
correlation test was used to determine correlations
between variables, with r being the Spearman correla-
tion coefficient. Statistical analysis was performed with
GraphPad Prism 5.01 software. P-values of < 0.05 were
considered statistically significant.
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Results
Characteristics of subjects studied
Table 1 outlines the characteristics of the 39 SLE sub-
jects and 10 healthy controls analyzed in this study. SLE
subjects were classified into two groups according to
treatment regimen: one group of 25 subjects received
hydroxychloroquine (HCQ) and another group of 14
subjects did not. Among the 25 subjects treated with
HCQ, 18 received 400 mg/day, 1 received 300 mg/day,
and 6 received 200 mg/day. The mean age of the SLE
subjects was 53 years and 36 (92%) were female. All
subjects were of self-described European descent. The
mean SLAQ score, defining lupus disease activity, was
10.4 (± 8.4). Twelve of the SLE subjects (30.8%) were
receiving prednisone at a daily dose that was less that
10 mg/day. Eight (20.5%) were also treated with immu-
nosuppressive medication, for example, cyclosporine
(n = 2), mycophenolate mofetil (n = 3), methotrexate
(n = 2), or azathioprine (n = 1). Compared to controls,
SLE subjects were older (53 ± 12.5 vs. 30 ± 4.3 years
old, P < 0.0001). Compared to SLE subjects being trea-
ted with HCQ, SLE subjects not receiving HCQ were
similar in terms of age, gender, disease activity and
other current treatment.
Plasmacytoid dendritic cells are responsible for IFN-a and
TNF-a production upon TLR-9/7 stimulation in both SLE
and healthy subjects
We first investigated the production of IFN-a and TNF-
a by PBMCs upon TLR-9 or TLR-7 stimulation in SLE
and healthy subjects. PBMCs from subjects with SLE and
healthy controls were stimulated in vitro for five hours
using the TLR-9 ligand, CpG-A ODN 2216, and the
TLR-7 ligand, imiquimod R837. IFN-a and TNF-a pro-
duction in monocytes (HLA-DR+CD14+), B cells (HLA-
DR+CD14-CD16-CD20+), myeloid dendritic cells
(mDCs, HLA-DR+CD14-CD16-CD20-CD11c+), pDCs
(HLA-DR+CD14-CD16-CD20-CD123+), and natural
killer cells (NK cells, HLA-DR-CD16+) was determined
using multiparameter flow cytometry (see Additional
file 1, Figure S1). In SLE and healthy subjects overall,
TLR-9 stimulation induced the production of IFN-a and
TNF-a in 0.3% (SD ± 0.3) and 0.8% (± 1.2) of monocytes,
1.3% (± 1.8) and 0.2% (0.2) of B cells, 1.2% (± 1.3) and
0.5% (0.6) of mDCs, and 7.5% (± 8.7) and 10.3% (± 13.5)
of pDCS (Figure 1A). After stimulation of TLR-7, a simi-
lar analysis of SLE and healthy subjects showed induction
of IFN-a and TNF-a in 0.4% (± 0.6) and 0.9% (± 1.1) of
monocytes, 1% (± 1.6) and 0.1% (± 0.1) of B cells, 0.8%
(± 1.3) and 0.4% (± 0.5) of mDCs, and 4.8% (± 5) and
5.5% (± 4.2) of pDCs (Figure 1B). Of these levels of
induction, those observed in pDCs from SLE patients and
controls were significantly higher than those observed in
the other cell subpopulations. No production of IFN-a or
TNF-a was noted in NK cells in either group or with
either stimulation. Therefore, among various subpopula-
tions of PBMCs, pDCs represent the major source of
IFN-a and TNF-a after TLR-9/7 stimulation in both SLE
and healthy subjects (see, for example, Figure 1C).
pDCs from SLE patients show impaired production of IFN-
a and TNF-a after TLR-9/7 stimulation
Upon TLR-9 stimulation with CpG, 19.2% (± 3.5) and 29%
(± 4) of pDCs from healthy subjects produced IFN-a and
TNF-a, respectively. By contrast, only 4.4% (± 0.7) and
8.1% (± 2.1) of pDCs from SLE subjects produced IFN-a
(P < 0.0001), as compared to healthy controls) and TNF-a
(P < 0.0001, as compared to healthy controls) (Figure 2A).
Likewise, the production of IFN-a and TNF-a by pDCs
upon TLR-7 stimulation with imiquimod was decreased in
SLE subjects (4% ± 0.6 and 4.4% ± 0.6, respectively) com-
pared to healthy controls (7.2% ± 2.5 and 8.6% ± 1.4,
respectively). However, only the difference in the TNF-a
production between these two groups was statistically sig-
nificant (P = 0.01) (Figure 2B).
To determine if the proportion of pDCs in subjects
with SLE was also low (as has been reported [12]), we
examined the proportion of pDCs (as defined by the
Table 1 Characteristics of SLE patients and healthy controls studied
Healthy SLE subjects




Age, years (SD) 30 (4.3)1 53 (12.5)1 50.4 (12.7) 57.6 (11.2)
Female, n (%) 8 (80%) 36 (92%) 22 (88%) 14 (100%)
European ancestry, n (%) 10 (100%) 39 (100%) 25 (100%) 14 (100%)
Years since SLE diagnosis (SD) 19.2 (9.7) 17.2 (9.4) 22.7 (9.6)
SLE activity (SLAQ) 10.4 (8.4) 11.8 (8.9) 8.1 (7.3)
Treatment
prednisone, n (%) 12 (30.8%) 9 (36%) 3 (21.4%)
immunosuppressant, n (%) 8 (20.5) 5 (20%) 3 (21.4%)
1, P < 0.0001. HCQ, hydroxycholoroquine; SD, standard deviation; SLAQ, Systemic Lupus Activity Questionnaire; SLE, systemic lupus erythematosus
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percentage of HLA-DR+, CD123+ cells, relative to all
singlet, live cells). At least in this study, the mean per-
centage of pDCs in SLE subjects (0.46% ± 0.3) did not
differ significantly from that observed in healthy con-
trols (0.37% ± 0.1; P = 0.98) (Figure 3A). Moreover, the
percentage of pDCs did not significantly differ between
SLE subjects receiving (0.42% ± 0.33) or not receiving
(0.48% ± 0.28) HCQ (P = 0.50) (Additional file 1, Figure
S2A).
We then examined the relationship between the level
of pro-inflammatory cytokines (that is, IFN-a and TNF-
a) produced by pDCs and the clinical activity of SLE (as
defined using the Systemic Lupus Activity Question-
naire, or SLAQ). No statistical correlation was found
between the production of IFN-a and TNF-a upon
TLR-9/7 stimulation and the SLAQ scores (Figure 3B).
The ability of pDCs to produce IFN-a/TNF-a upon
TLR-9/7 stimulation was also not associated with age
(age and TLR-9/IFN-a, r = 0.20, P = 0.21) (age and
TLR-9/TNF-a, r = 0.20, P = 0.24) (age and TLR-7/IFN-
a, r = 0.12, P = 0.45) (age and TLR-7/TNF-a, r = 0.01,
P = 0.95) (Additional file 1, Figure S2B).
pDC production of IFN-a and TNF-a upon TLR-9/7
stimulation is dramatically reduced in SLE subjects
treated with HCQ
IFN-a and TNF-a production by pDCs upon TLR-9 and
TLR-7 stimulation was severely impaired (< 1% of
CD123+ IFN-a+/TNF-a+) in 36% (14 subjects) and 33%









Figure 1 Plasmacytoid dendritic cells are responsible for IFN-a and TNF-a production upon TLR-9/7 stimulation. Flow cytometric
analysis of IFN-a (left) and TNF-a (right) production after TLR-9 (A) or TLR-7 (B) stimulation of monocytes (CD14+), B cells (CD20+), mDCs
(CD11c+), pDCs (CD123+), and NK cells (CD16+) found in the PBMCs of SLE patients (n = 39, white circles) and healthy (n = 10, black circles)
(see supplementary Figure S1 for details on phenotypic analysis). The lines represent the median IFN-a/TNF-a production by subsets of PBMCs.
(C) Flow cytometric analysis of IFN-a and TNF-a production after media (No Stim, top), TLR-9 (middle) and TLR-7 (bottom) stimulation of
plasmacytoid dendritic cells (pDCs), (HLA-DR+CD14-CD16-CD20-) CD123+ in one representative subject. *, refers to P < 0.05, ** refers to P <
0.005, *** refers to P < 0.0001.
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all of the 14 SLE subjects with impaired TLR-9 induced
IFN-a production and 11 of 13 with impaired TLR-7
induced IFN-a production were being treated with
HCQ (impaired TLR-9/IFN-a; HCQ vs no HCQ; P =
0.0003) (impaired TLR-7/IFN-a; HCQ vs no HCQ; P =
0.07). Likewise, 13 of the 14 SLE subjects with impaired
TNF-a production upon TLR-9 stimulation (HCQ vs no
HCQ; P < 0.009) and 12 of the 13 subjects with
impaired TNF-a production upon TLR-7 stimulation
(HCQ vs no HCQ; P < 0.01) were being treated with
HCQ.
Overall, pDC production of IFN-a and TNF-a upon
TLR-9 and TLR-7 stimulation was lower in SLE subjects
treated with HCQ (TLR-9: 2% ± 2.2 CD123+IFN-a+;
1.4% ± 2.9 CD123+TNF-a+) (TLR-7: 3.3% ± 3.8 CD123
+IFN-a+; 3.7% ± 3.7 CD123+TNF-a+) compared to
SLE subjects who were not receiving HCQ (TLR-9: 8.6%
± 4.3 CD123+IFN-a+, P < 0.0001; 11.8% ± 9.1 CD123
+TNF-a+, P < 0.0001) (TLR-7: 5.3% ± 3.9 CD123+IFN-
a+, P = 0.058; 7.4% ± 7.4 CD123+TNF-a+, P = 0.054)
(Figure 4). This difference was highly significant (P <
0.0001) in the case of TLR-9 stimulation and trended
towards significance (P < 0.06) in the case of TLR7 sti-
mulation. We did not observe any significant differences
in IFN-a/TNF-a production by TLR-9/7-stimulated
pDCs between subjects receiving 400 mg/day and 200
mg/day (TLR-9/IFN-a, P = 0.35) (TLR-9/TNF-a, P =
0.27) (TLR-7/IFN-a, P = 0.42) (TLR-7/TNF-a, P = 0.13)
(Additional file 1, Figure S3). Interestingly, HCQ treat-
ment did not have any effect on the production of TNF-
a by monocytes (CD14+) and mDCs (CD11c+) upon
TLR-4 stimulation. Indeed, among SLE patients receiv-
ing HCQ or not, 22.2% (± 14.7) and 16% (± 10.4) of
monocytes, respectively, produced TNF-a after five
hours of in vitro lipopolysaccharide (LPS) stimulation







Figure 2 pDCs from SLE patients show impaired production of IFN-a and TNF-a after TLR-9/7 stimulation. Comparison of the frequency
of circulating pDCs (CD123+ cells) producing IFN-a (left) and TNF-a (right) after TLR-9 (A) or TLR-7 (B) stimulation between SLE subjects (n = 39,
white circles) and healthy controls (n = 10, black circles). In each case, the lines represent the mean value and the error bars show the standard
deviation.
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mDCs produced TNF-a upon LPS stimulation among
SLE patients receiving HCQ or not (P = 0.74) (Figure 5).
Discussion
Ongoing IFN-a production in SLE patients appears to
play an important pathogenic role in the autoimmune
process and pDCs have a pivotal role as the main pro-
ducers of IFN-a in vivo [9,27]. For this reason, different
regimens directed against IFN-a are of high therapeutic
benefit in SLE. In this study, we found that pDC pro-
duction of IFN-a and TNF-a upon TLR-9 or TLR-7 sti-
mulation was markedly reduced in SLE patients treated
with HCQ. Although HCQ has been shown to act as a
TLR-9 and TLR-7 antagonist in vitro, these data demon-
strate that it also inhibits TLR-9 and TLR-7 stimulation
in vivo. Such inhibition is also specific, in that HCQ
treatment has little effect on TLR-4-induced production
of TNF-a by monocytes and mDCs. Thus, our data pro-
vide new insights regarding the mechanism of action of
HCQ in SLE. The reduction of TNF-a TLR-9/7-induced
pDC production observed with HCQ is interesting from
a therapeutic point of view, even if the involvement of
TNF-a in the pathogenesis of SLE remains controversial
[28]. Interestingly, a recent paper has shown that circu-
lating TNF-a and type I IFN levels are correlated in a
large cohort of SLE patients [29]. Finally, similar obser-
vations have been made in HCQ-treated HIV-infected
“immunologic non-responders” [28], a condition in
which chronic exposure to IFN-a may also lead to
immune dysfunction [30].
One puzzling and previously reported result is the over-




Figure 3 Frequency of circulating pDCs, pDCs IFN-a+/TNF-a+ after TLR-9/7 stimulation and lupus disease activity. (A) Flow cytometric
analysis of pDCs (HLA-DR+CD123+ cells) found in the PBMCs in one representative subject (left). Comparison of the frequency of circulating
pDCs found in SLE subjects (white circles) and healthy controls (black circles) (right). (B) Absence of statistical correlation between the frequency
of CD123+ pDCs IFN-a+ (white triangles) or TNF-a+ (black triangles) after TLR-9 (left) or TLR-7 (right) stimulation and disease activity assessed by
using the Systemic Lupus Activity Questionnaire (SLAQ) in SLE patients (TLR-9 stimulation: IFN-a/SLAQ, r = -0.20, P = 0.23; TNF-a/SLAQ, r = -0.08,
P = 0.62) (TLR-7 stimulation: IFN-a/SLAQ, r = -0.18, P = 0.28; TNF-a/SLAQ, r = -0.01, P = 0.96). In each case, the lines represent the mean value
and the error bars show the standard deviation.
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compared to controls [11-13]. It has been hypothesized
that the reduced ability of pDCs to produce IFN-a may be
a consequence of the redistribution of the efficient pDCs
into tissues [31] or of the exhaustion of circulating pDCs
as a consequence of a high level of stimulation by persis-
tent endogenous IFN-a inducing factors [13]. Although
pDCs are probably migrating to tissues and producing
IFN- a there, we did not observe any difference in the per-
centage of circulating pDCs between SLE patients and
healthy controls. We did not either observe any associa-
tion with IFN-a production by in vitro stimulated pDCs
and SLE disease activity. Kwok et al. [13] previously
showed that repeated stimulation of pDC with TLR-9
ligand decreased levels of IFN-a production. These
authors concluded that the persistent presence of endo-
genous IFN-a-inducing factors induced TLR tolerance in
pDCs of SLE patients. We have now demonstrated that, at
least in some patients, such “tolerance” is strongly
correlated with the exogenous administration of HCQ. In
fact, most of the SLE patients in previous studies who
showed decreased IFN-a production were receiving HCQ
[11-13]. Our comprehensive study of all subsets of PBMCs
potentially targeted by TLR-9/7 ligand also excludes the
possibility that other circulating mononuclear cells
(besides pDCs) may produce IFN-a. It would have been of
interest to determine IFN-a levels and the absolute num-
ber of pDCs in the circulation, but such measurements are
themselves only uncertain surrogates of the IFN-a and
pDC levels in tissues, where most of the pathology of SLE
plays out. Although conflicting data may result from the
use of different methods to isolate and culture the pDCs
between studies, our results support a key role for HCQ
treatment in explaining the impaired functional ability of
pDCs in SLE.
Low serum HCQ levels have been reported to be a
marker for and a predictor of SLE exacerbations [32],
A 
B 
HCQ No HCQ HCQ No HCQ 
HCQ No HCQ HCQ No HCQ 
Figure 4 pDC production of IFN-a/TNF-a upon TLR-9/7 stimulation in SLE subjects treated with HCQ. Comparison of the frequency of
pDCs (CD123+ cells) producing IFN-a (left) and TNF-a (right) after TLR-9 (A) or TLR-7 (B) stimulation between SLE subjects that were treated (n
= 25, white squares) or not (n = 14, black triangles) with HCQ. In each case, the lines represent the mean value and the error bars show the
standard deviation.
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leading to the question of a possible relationship
between blood HCQ concentrations and efficacy. We
did not observe any significant differences in IFN-a/
TNF-a production by TLR-7/9-stimulated pDCs
between subjects receiving 400 mg/day and 200 mg/day.
We do not know, however, the extent to which each
patient was compliant with treatment and serum HCQ
levels were not routinely measured.
Lupus activity is commonly measured by valid and
reliable disease activity physician-rated scores, such as
the Systemic Lupus Activity Measure (SLAM) [33], the
Systemic Lupus Erythematosus Disease Activity Index
(SLEDAI) [34], or the British Isles Lupus Assessment
Group (BILAG) [35]. All assess cumulative disease activ-
ity, including not only parameters that are immunologi-
cal (for example, the level of antibodies against dsDNA
and complement) but also clinical and biological. Practi-
cal considerations limited our ability to obtain all of the
biological and immunological parameters required to
calculate the SLEDAI or BILAG scores.
The SLAQ is a patient-reported assessment of subjec-
tive disease activity in SLE that has been shown to cor-
relate strongly (r = 0.62) with the SLAM-omitting
laboratory items [26] and is considered to be the best
measure of self-reported disease activity in the field. It
also has the advantage of being the most cost effective
way to track disease activity. Using a cutoff score of 13
points on the SLAQ results in a negative predictive
value of 74% for clinically important disease activity [26]
defined by a SLAM-omitting laboratory items score ≥3
points. In our study, 30 (77%) subjects had a SLAQ
score that was less than 13 and the mean SLAQ score
was 10.4. We did not observe an association between
TLR-9/7 induced IFN-a production by pDCs and SLE
disease activity. However, most of the patients studied




























HCQ No HCQ 




Figure 5 Monocytes and mDCs production of IFN-a/TNF-a upon TLR-4 stimulation in SLE subjects treated with HCQ. Flow cytometric
analysis (left) of IFN-a and TNF-a production after TLR-4 (lipopolysaccharide, LPS) stimulation of monocytes (CD14+) (top, left) and mDCs,
(CD11c+) (bottom) in a representative subject. Comparison of the frequency of monocytes (CD14+) (right top) and mDCs (CD11c+) (right
bottom) cells producing TNF-a after TLR-4 stimulation between SLE subjects that were treated (white squares) or not (black triangles) with HCQ.
In each case, lines represented the mean value and error bars the standard deviation.
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the number of subjects included, our study may have
lacked power to fully address this question.
Conclusions
Despite evidence supporting beneficial effects of HCQ
treatment in SLE, few clinical studies have been per-
formed to elucidate the specific mechanisms of action.
Our data suggest that HCQ is of therapeutic benefit in
SLE because its use is associated with impairment of the
in vivo production of IFN-a and TNF-a by circulating
pDCs upon stimulation of TLR-9 and TLR-7. Possibly
its efficacy is limited because it more effectively inhibits
TLR9 than TLR7 responses. If so, this would provide
impetus for the development of additional TLR-7 and
TLR-9 antagonists to use as possible treatment options
for SLE.
Additional material
Additional file 1: Table S1. Panel of antibodies used. Additional file 1,
Figure S1. Flow cytometry gating Strategy. Gating strategy by flow
cytometry for the detection of monocytes (singlet1 (forward scatter A
(FSC-A) × FSC-H diagonal), live (Aqua)-, HLA-DR+, CD14+ cells), NK
(singlet, live, HLA-DR-, CD16+ cells), B cells (singlet, live, HLA-DR+, CD14-,
CD20+ cells), mDCs (singlet, live, HLA-DR+, CD14- cells, CD20-, CD11c+)
and pDCs (singlet, live, HLA-DR+, CD14- cells, CD20-, CD123+). 1 gated
singlet live means that all potential doublets were excluded from the
analysis. Additional file 1, Figure S2. Frequency of circulating pDCs, pDCs
IFN-a+/TNF-a+ after TLR-9/7 stimulation and age. (A) Comparison of the
frequency of circulating pDCs found in SLE subjects receiving (black
circles) or not (black squares) hydroxychloroquine (HCQ). (B) Absence of
statistical correlation between the frequency of CD123+ pDCs IFN-a+
(white triangles) or TNF-a+ (black triangles) after TLR-9 (left) or TLR-7
(right) stimulation and age. Additional file 1, Figure S3. pDC production
of IFN-a/TNF-a upon TLR-9/7 stimulation in SLE subjects treated with
HCQ. Comparison of the frequency of pDCs (CD123+ cells) producing
IFN-a (left) and TNF-a (right) after TLR-9 (A) or TLR-7 (B) stimulation
between SLE subjects that were receiving 200 mg (HCQ 200 mg, black
circles) or 400 mg (HCQ 400 mg, black squares) of hydroxychloroquine
(HCQ).
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